Soleno Therapeutics (SLNO) Cash from Financing Activities (2014 - 2026)

Soleno Therapeutics (SLNO) has 12 years of Cash from Financing Activities data on file, last reported at -$1.0 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$1.0 million, down 132.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $132.9 million (down 38.27% YoY), and the FY2025 annual result was $137.2 million, down 35.61% from the prior year.
• Cash from Financing Activities improved to -$1.0 million in Q1 2026 per SLNO's latest filing, from -$99.9 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $218.2 million in Q3 2025 and troughed at -$99.9 million in Q4 2025.
• A 5-year average of $36.2 million and a median of $14.0 million in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities slumped 14200.0% in 2022, then soared 11420.76% in 2023.
• A 5-year view of Cash from Financing Activities shows it stood at $342000.0 in 2022, then soared by 36028.07% to $123.6 million in 2023, then slumped by 53.82% to $57.1 million in 2024, then plunged by 275.07% to -$99.9 million in 2025, then jumped by 98.96% to -$1.0 million in 2026.
• Business Quant data shows SLNO's Cash from Financing Activities at -$1.0 million in Q1 2026, -$99.9 million in Q4 2025, and $218.2 million in Q3 2025.